PureTech Health (PRTC) Cash & Equivalents (2019 - 2024)
PureTech Health (PRTC) has disclosed Cash & Equivalents for 6 consecutive years, with $280.6 million as the latest value for Q4 2024.
- Quarterly Cash & Equivalents rose 46.87% to $280.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $280.6 million through Dec 2024, up 46.87% year-over-year, with the annual reading at $280.6 million for FY2024, 46.87% up from the prior year.
- Cash & Equivalents for Q4 2024 was $280.6 million at PureTech Health, up from $191.1 million in the prior quarter.
- The five-year high for Cash & Equivalents was $465.7 million in Q4 2021, with the low at $149.9 million in Q4 2022.
- Average Cash & Equivalents over 5 years is $298.2 million, with a median of $280.6 million recorded in 2024.
- The sharpest move saw Cash & Equivalents surged 205.14% in 2020, then plummeted 67.82% in 2022.
- Over 5 years, Cash & Equivalents stood at $403.9 million in 2020, then rose by 15.31% to $465.7 million in 2021, then tumbled by 67.82% to $149.9 million in 2022, then increased by 27.5% to $191.1 million in 2023, then surged by 46.87% to $280.6 million in 2024.
- According to Business Quant data, Cash & Equivalents over the past three periods came in at $280.6 million, $191.1 million, and $149.9 million for Q4 2024, Q4 2023, and Q4 2022 respectively.